Navigation Links
GeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results
Date:2/25/2011

, antiretroviral treatment in low and middle income countries was restricted to about 3 million people. In the United States, about 50% of those who are infected are estimated to be on drug treatment.

Forward-Looking StatementsCertain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act.  These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether:  HVTN will commence, complete enrollment, and generate data regarding GeoVax vaccine clinical trials as and when expected, GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective, less costly, or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.

FINANCIAL TABLES FOLLOWGEOVAX LABS, INC.Statements of Operations Data(amounts in thousands, except per share data)Three Months Ended

Year EndedDecember 31,

December 31, 2010

2009

2010

2009Grant Revenue$  946

$  397

$  5,185

$  3,668
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
2. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
3. GeoVax Presents Data at AIDS Vaccine 2008 Conference
4. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
5. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
6. GeoVax to Present at the BIO CEO & Investor Conference 2009
7. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
8. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
9. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results
10. GeoVax Labs, Inc. Announces First Quarter Financial Results
11. GeoVax to Exhibit at the 2009 BIO International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... 2015 /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced ... Resverlogix have approved the resolutions relating to: (i) ... 5,600,000 units at a price of $2.67 per ... comprised of one common share and 0.075358 common ... CAD$15 million; and (ii) the amendment to Resverlogix,s ...
(Date:6/30/2015)... ... June 30, 2015 , ... uBiome and OpenBiome Partner ... mechanics of fecal microbiota transplantation in C. difficile patients. , SAN FRANCISCO, uBiome ... undergoing fecal microbiota transplantation (FMT) as a treatment for Clostridium difficile infections (C. ...
(Date:6/30/2015)... , June 30, 2015  The University of ... Biosciences (CCE/Bio) and UC San Diego Extension announced ... be held Aug.  12 – 14, 2015, at ... three-day workshop provides an intense exposure to best ... and is well-suited to biologists, process engineers and ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... prior to launching SmartArch — a revolutionary new archwire that allows orthodontists to ... further clinical evidence of the efficacy of SmartArch. “We’re thrilled about taking SmartArch ...
Breaking Biology Technology:Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3UC San Diego Extension to Offer Third Annual Microbial Fermentation Workshop 2New case studies for SmartArch orthodontic archwire paves way to product launch later this year 2
... , - Microplasmin Shows Clear Promise in ... Macular Hole Closure and Traction Release,Without Need for ... biotechnology company,focused on vascular and eye diseases, will ... trial at the American Society of Retina Specialists,(ASRS) ...
... A preliminary design review has concluded and verified the ... Element on NASAs James Webb Space Telescope. , The ... the Webb Observatory. The telescope consists of a 6.5-meter ... mirrors; and supporting structures, deployable tower and control electronics. ...
... high blood pressure(1); increase in pediatric cases linked to growing ... ... safety profile in adults with high blood pressure, EAST HANOVER, N.J., ... approved following a priority,review by the U.S. Food and Drug Administration (FDA) ...
Cached Biology Technology:ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting 2ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting 3ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting 4James Webb Space Telescope marks successful completion 2FDA Approves Diovan(R) for Treatment of High Blood Pressure in Children 2FDA Approves Diovan(R) for Treatment of High Blood Pressure in Children 3FDA Approves Diovan(R) for Treatment of High Blood Pressure in Children 4FDA Approves Diovan(R) for Treatment of High Blood Pressure in Children 5
(Date:6/16/2015)... /CNW Telbec/ - handyem Inc. and FlowMetric Diagnostics ... of handyem,s HPC-150 portable flow cytometer within FlowMetric ... unprecedented model of mobile laboratory platform is presented ... Pennsylvania Convention Center, ... to 18 th 2015.  By virtue of ...
(Date:6/15/2015)... -- According to a new market research ... and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image ... The Natural Language Processing Market is expected to grow ... the forecast period 2015-2020. Browse 65 ... spread   through 155 P ages and in-depth ...
(Date:6/11/2015)... RESTON, Va. , June 11, 2015 /PRNewswire/ ... authentication technology, announced today that its IdentityX Mobile ... FIDO (Fast IDentity Online) Alliance is an industry ... with open standards for simpler, stronger authentication.  In ... services must pass a rigorous series of tests ...
Breaking Biology News(10 mins):handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2
... Conservation Biology Institute and George Mason University broke ... that embodies the concept of the living classroom. ... Program has trained future conservationists with an interdisciplinary ... National Zoological Park,s 3,200-acre facility in Front Royal, ...
... MDAs strange as it sounds, a new research study ... ), suggests that the "healthy" ingredient in red wine, ... sedentary lifestyles have on people. The report describes experiments ... which the group fed resveratrol did not develop insulin ...
... song from a bird of the same species, a zebra finch ... a time, occasionally cocking its head but otherwise immobile. Once it ... routine. ( See video .) In a new study ... ribonucleic acid that appear to regulate protein production go up ...
Cached Biology News:Smithsonian Conservation Biology Institute and George Mason University expand partnership 2MicroRNAs in the songbird brain respond to new songs 2
Agarose for baculovirus plaque assays which allow optimal growth of plated insect cells....
BD BaculoGold Max-XP Insect Cell Medium 1 Liter...
Mycoplasma and virus tested...
Edited by I.H. Pawlowitzki, J.H. Edwards and E.A. Thompson (1997) • This volume covers: Linkage in dominant recessive and oligogenic disease, Model free (non-parametric) methods, Tools for gene ...
Biology Products: